Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes

AIMS: Two fixed‐ratio combinations (FRCs) of basal insulin and glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) are available for once‐daily use in adults with type 2 diabetes. We aimed to review the clinical evidence for the efficacy and safety of changing treatment from a basal–bolus insulin (BB...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Roopa, Billings, Liana K., Liebl, Andreas, Vilsbøll, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542161/
https://www.ncbi.nlm.nih.gov/pubmed/35708737
http://dx.doi.org/10.1111/dme.14901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542161/
https://www.ncbi.nlm.nih.gov/pubmed/35708737
http://dx.doi.org/10.1111/dme.14901

Ejemplares similares